JSJ Pharmaceuticals Announces Authorized Generic Agreement

CHARLESTON, S.C., April 4 — JSJ Pharmaceuticals is pleased to announce that, as part of its long-term brand life cycle management, it has reached an agreement with an undisclosed generic pharmaceutical partner to provide authorized generic versions of JSJ brands. While such an arrangement is important to the late stages of a brand’s life cycle, it is critical that long-term planning is in place for rapid strategic execution. “At some point, a brand will lose its market exclusivity; an authorized generic partner provides JSJ with an important tool in the late-stage life cycle management of its brands and will let us respond quickly to changes in market conditions,” stated JSJ’s Chief Operating Officer, Jonathan Alba.

JSJ Pharmaceuticals Assumes Sales & Marketing Responsibility of Oxsoralen-Ultra® from Valeant Pharmaceuticals International

JSJ Pharmaceuticals Assumes Sales & Marketing Responsibility of Oxsoralen-Ultra® from Valeant Pharmaceuticals International
CHARLESTON, S.C., Feb. 7 — JSJ Pharmaceuticals today announced a multi-year agreement under which it has assumed from Valeant Pharmaceuticals International (NYSE:VRX) the sales, marketing, and educational responsibilities for Oxsoralen-Ultra® (Methoxsalen capsules, USP, 10mg), 8-MOP® Capsules (Methoxsalen capsules, USP 10mg), and Oxsoralen Lotion 1% (Methoxsalen, USP, 1%). Oxsoralen-Ultra® is an important product for the treatment of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy.

“This partnership with Valeant Pharmaceuticals represents a great opportunity for JSJ Pharmaceuticals to continue providing clinicians with the ‘toolbox’ of products for the management of clinical challenges faced on a daily basis in their practices and continues to provide patients suffering from recalcitrant psoriasis with treatment options for relief from this debilitating disease,” said JSJ’s Chief Operating Officer, Jonathan Alba.

About Psoriasis disease:
Psoriasis is an inflammatory skin condition and frequently is associated with “plaques” which appear as patches of raised, reddish skin covered by silvery-white scale. The skin often itches, and may crack and bleed which usually causes discomfort. Psoriasis is a lifelong skin disease during which patients experience periods of flares and remissions. As many as 7.5 millions Americans have psoriasis according to the National Institutes of Health, and approximately 150,000 new cases are diagnosed each year according to the American Academy of Dermatology.

Important Safety Information
Methoxsalen with UV radiation should be used only by physicians who have special competence in the diagnosis and treatment of psoriasis and who have special training and experience in photochemotherapy. The use of Psoralen and ultraviolet radiation therapy should be under constant supervision of such a physician. For the treatment of patients with psoriasis, photochemotherapy should be restricted to patients with severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis is certain. Because of the possibilities of ocular damage, aging of the skin, and skin cancer (including melanoma), the patient should be fully informed by the physician of the risks inherent in this therapy.

CAUTION: Oxsoralen-Ultra® (Methoxsalen Soft Gelatin Capsules) should not be used interchangeably with regular Oxsoralen® or 8-MOP® (Methoxsalen Hard Gelatin Capsules). This new dosage form of methoxsalen exhibits significantly greater bioavailability and earlier photosensitization onset time than previous methoxsalen dosage forms. Patients should be treated in accordance with the dosimetry specifically recommended for this product. The minimum phototoxic dose (MPD) and phototoxic peak time after drug administration prior to onset of photochemotherapy with this dosage form should be determined.

Pharmaceutical Company Locates Corporate Headquarters to Charleston, SC

Charleston, South Carolina --January 23, 2007 -- JSJ Pharmaceuticals, Inc. (JSJ), a specialty pharmaceutical company that identifies and brings to market pharmaceutical products targeted for topical use, primarily in the dermatology community, has located their corporate headquarters to 140 East Bay Street in downtown Charleston, South Carolina. Incorporated in 2003, JSJ promotes its own line of products that started with three products in October 2003. Today, as a result of R&D and acquisition, JSJ sells over 15 product lines.

JSJ Pharmaceutical COO, Jonathan Alba, cited access to the dermatology program at the Medical University of South Carolina (MUSC) as a key consideration for choosing to locate his company’s headquarters from Philadelphia, Pennsylvania to Charleston, South Carolina. “Having access to the well renowned research staff in the Dermatology department at MUSC is critical to a rapidly growing company like JSJ,” he stated. Charleston’s lifestyle, availability of talent and competitive business climate were also strong considerations, he added.

Regarding the relationship between JSJ and MUSC, Bruce Thiers, MD, Chairman, Department of Dermatology stated "Partnerships between academia and industry are becoming increasingly important in the advancement of health care. I'm confident that we can build a strong relationship between the Department of Dermatology and JSJ Pharmaceuticals."

JSJ continues to identify and develop additional prescriptive dermatology products to complement and/or expand their current product line, leverage its patented technology and expand the company’s overall presence as a progressive dermatology company. The company is expected to introduce several new products or line extensions in 2007 and launch into the rapidly growing aesthetic dermatology market segment in 2008.

JSJ Pharmaceuticals corporate office is located in the Charleston Digital Corridor’s, Wharf District. “I am pleased to welcome JSJ to Charleston”, said Mayor Joseph P. Riley, Jr. “JSJ is joining the growing ranks of life sciences companies that recognize the value of MUSC, a world class medical university,” he added.

South Carolina Secretary of Commerce, Joe E. Taylor, congratulated JSJ Pharmaceuticals on their decision to locate their company to Charleston. “I am confident that JSJ will find all the ingredients necessary to accelerate the growth of their specialty pharmaceutical company in South Carolina,” he said.